JGC
TARS icon

J. Goldman & Co’s Tarsus Pharmaceuticals TARS Stock Holding History

J. Goldman & Co’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Buy
26,800
+12,259
+84% +$783K 0.04% 374
2026
Q1 		$1.02M Buy
14,541
+11,842
+439% +$827K 0.03% 415
2025
Q4 		$221K Sell
2,699
-41,601
-94% -$3.11M 0.01% 507
2025
Q3 		$2.63M Sell
44,300
-320,257
-88% -$15.8M 0.07% 259
2025
Q2 		$14.8M Buy
364,557
+224,269
+160% +$10.1M 0.35% 95
2025
Q1 		$7.21M Buy
140,288
+10,093
+8% +$499K 0.18% 164
2024
Q4 		$7.21M Sell
130,195
-427,305
-77% -$19.4M 0.19% 166
2024
Q3 		$18.3M Buy
557,500
+170,339
+44% +$4.79M 0.51% 54
2024
Q2 		$10.5M Buy
387,161
+223,814
+137% +$7.53M 0.3% 104
2024
Q1 		$5.94M Buy
163,347
+91,003
+126% +$2.68M 0.19% 135
2023
Q4 		$1.46M Sell
72,344
-53,565
-43% -$894K 0.06% 209
2023
Q3 		$2.24M Buy
125,909
+69,937
+125% +$1.24M 0.08% 195
2023
Q2 		$1.01M Buy
55,972
+14,399
+35% +$229K 0.04% 250
2023
Q1 		$523K Hold
41,573
– – 0.02% 266
2022
Q4 		$609K Hold
41,573
– – 0.03% 266
2022
Q3 		$712K Sell
41,573
-9,253
-18% -$147K 0.03% 276
2022
Q2 		$742K Buy
50,826
+40,282
+382% +$605K 0.04% 263
2022
Q1 		$177K Buy
+10,544
New +$196K 0.01% 322
2021
Q4 		– Sell
-22,198
Closed -$478K – 438
2021
Q3 		$478K Sell
22,198
-11,553
-34% -$286K 0.02% 277
2021
Q2 		$978K Buy
+33,751
New +$1.05M 0.04% 283

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

J. Goldman & Co's TARS Position: Q2 2026 in Review

J. Goldman & Co increased its Tarsus Pharmaceuticals (TARS) stake by 84% in Q2 2026, buying an estimated $783K and bringing the position to 26,800 shares worth $1.69M. The position accounts for 0.04% of the portfolio, ranked #374.

J. Goldman & Co first reported a position in TARS in Q2 2021 and has held it in 20 quarters since. The position peaked at $18.3M in Q3 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • J. Goldman & Co held 26,800 shares of Tarsus Pharmaceuticals worth $1.69M as of Q2 2026.
  • J. Goldman & Co bought 12,259 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $783K.
  • Tarsus Pharmaceuticals made up 0.04% of J. Goldman & Co's portfolio in Q2 2026, its #374 holding.
  • J. Goldman & Co first reported a position in Tarsus Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • J. Goldman & Co's Tarsus Pharmaceuticals position peaked at $18.3M in Q3 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.